P/E ratio for BrainStorm Cell Therapeutics (BCLI)

P/E ratio history for BrainStorm Cell Therapeutics from 2003 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Biogen BIIB	17.1	-3,456.51%	🇺🇸 USA
Gilead Sciences GILD	22.3	-4,470.95%	🇺🇸 USA
Seagen SGEN	-57.0	11,087.72%	🇺🇸 USA
Cytokinetics CYTK	-9.71	1,805.33%	🇺🇸 USA
Agenus AGEN	-1.02	100.54%	🇺🇸 USA
Acceleron Pharma XLRN	N/A	N/A	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.